Dual Targeting of GPRC5D and BCMA Gets High Response Rate in Extramedullary Myeloma

By News Health
1 hour Ago

(MedPage Today) — ORLANDO — For triple-class exposed relapsed or refractory multiple myeloma with extramedullary disease (EMD), a combination of talquetamab (Talvey) and teclistamab (Tecvayli) achieved high response rates in updated results…

Source link : https://www.medpagetoday.com/meetingcoverage/ashhematology/118891

Author :

Publish date : 2025-12-08 19:32:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

New Device Uses Steam to Kill Prostate Cancer

Trial Results Could Shuffle Order of BTK Inhibitors for CLL/SLL

Drug Combo Shows Benefits in Fit Patients With Acute Myeloid Leukemia

Many Patients Still Face GP Referral ‘Black Hole’

Adding Procedures, Cutting the Paperwork

CDC Panel Targets Size of Childhood Vaccine Schedule, Safety of Aluminum Adjuvants